GEP20053494B - Crystalline Therapeutic Agent - Google Patents

Crystalline Therapeutic Agent

Info

Publication number
GEP20053494B
GEP20053494B GE5062A GEAP2001005062A GEP20053494B GE P20053494 B GEP20053494 B GE P20053494B GE 5062 A GE5062 A GE 5062A GE AP2001005062 A GEAP2001005062 A GE AP2001005062A GE P20053494 B GEP20053494 B GE P20053494B
Authority
GE
Georgia
Prior art keywords
therapeutic agent
crystalline therapeutic
crystalline
ethylpipera
pharmacochemistry
Prior art date
Application number
GE5062A
Other languages
English (en)
Inventor
Laurence James Harris
Richard Anthony Storey
Albert Shaw Wood
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0018656A external-priority patent/GB0018656D0/en
Priority claimed from GB0106464A external-priority patent/GB0106464D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of GEP20053494B publication Critical patent/GEP20053494B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
GE5062A 2000-07-28 2001-07-18 Crystalline Therapeutic Agent GEP20053494B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0018656A GB0018656D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds
GB0106464A GB0106464D0 (en) 2001-03-15 2001-03-15 Crystalline therapeutic agent

Publications (1)

Publication Number Publication Date
GEP20053494B true GEP20053494B (en) 2005-04-25

Family

ID=26244756

Family Applications (1)

Application Number Title Priority Date Filing Date
GE5062A GEP20053494B (en) 2000-07-28 2001-07-18 Crystalline Therapeutic Agent

Country Status (45)

Country Link
EP (1) EP1305314B1 (en:Method)
JP (1) JP2004505087A (en:Method)
KR (1) KR100457937B1 (en:Method)
CN (1) CN1207297C (en:Method)
AP (1) AP1400A (en:Method)
AR (1) AR032628A1 (en:Method)
AT (1) ATE286901T1 (en:Method)
AU (2) AU2001272690B2 (en:Method)
BG (1) BG107266A (en:Method)
BR (1) BR0112734A (en:Method)
CA (1) CA2417264C (en:Method)
CZ (1) CZ2003126A3 (en:Method)
DE (1) DE60108398T2 (en:Method)
DO (1) DOP2001000217A (en:Method)
DZ (1) DZ3364A1 (en:Method)
EA (1) EA004681B1 (en:Method)
EC (1) ECSP034454A (en:Method)
EE (1) EE200300045A (en:Method)
ES (1) ES2231521T3 (en:Method)
GE (1) GEP20053494B (en:Method)
HR (1) HRP20030061A2 (en:Method)
HU (1) HUP0302982A3 (en:Method)
IL (1) IL153226A0 (en:Method)
IN (1) IN2002MU01649A (en:Method)
IS (1) IS6626A (en:Method)
MA (1) MA26931A1 (en:Method)
MX (1) MX233602B (en:Method)
MY (1) MY117831A (en:Method)
NO (1) NO324220B1 (en:Method)
NZ (1) NZ523226A (en:Method)
OA (1) OA12337A (en:Method)
PA (1) PA8523501A1 (en:Method)
PE (1) PE20020277A1 (en:Method)
PH (1) PH12001001922B1 (en:Method)
PL (1) PL365133A1 (en:Method)
PT (1) PT1305314E (en:Method)
SK (1) SK572003A3 (en:Method)
SV (1) SV2001000570A (en:Method)
TN (1) TNSN01112A1 (en:Method)
TW (1) TWI285643B (en:Method)
UA (1) UA72631C2 (en:Method)
UY (1) UY26854A1 (en:Method)
WO (1) WO2002010171A1 (en:Method)
YU (1) YU4703A (en:Method)
ZA (1) ZA200301457B (en:Method)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
OA13050A (en) 2003-04-29 2006-11-10 Pfizer Ltd 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
CA2562251C (en) 2004-04-07 2009-04-28 Pfizer Inc. Pyrazolo'4,3-d pyrimidines
NZ564187A (en) 2005-05-12 2010-03-26 Pfizer Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100449790B1 (ko) * 1998-04-20 2004-09-22 화이자 인코포레이티드 성기능장애를 치료하기 위한, 유형 5의 환상 구아노신3',5'-모노포스페이트 포스포디에스테라제에 대한피라졸로피리미디논 저해제
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Also Published As

Publication number Publication date
TNSN01112A1 (fr) 2005-11-10
HRP20030061A2 (en) 2003-04-30
EE200300045A (et) 2004-12-15
EP1305314A1 (en) 2003-05-02
SV2001000570A (es) 2002-09-03
UY26854A1 (es) 2002-02-28
IS6626A (is) 2002-11-18
CA2417264C (en) 2007-06-12
CN1444585A (zh) 2003-09-24
CA2417264A1 (en) 2002-02-07
SK572003A3 (en) 2004-05-04
MY117831A (en) 2004-08-30
KR100457937B1 (ko) 2004-11-20
IL153226A0 (en) 2003-07-06
NO20030416D0 (no) 2003-01-27
HK1055954A1 (en) 2004-01-30
BR0112734A (pt) 2004-08-10
AU2001272690B2 (en) 2005-12-08
AR032628A1 (es) 2003-11-19
NO324220B1 (no) 2007-09-10
PE20020277A1 (es) 2002-05-11
DE60108398T2 (de) 2005-12-22
OA12337A (en) 2006-05-15
EP1305314B1 (en) 2005-01-12
MX233602B (es) 2006-01-10
PA8523501A1 (es) 2002-10-24
ECSP034454A (es) 2003-03-10
EA004681B1 (ru) 2004-06-24
AP1400A (en) 2005-04-28
DZ3364A1 (fr) 2002-02-07
HUP0302982A2 (hu) 2003-12-29
PH12001001922B1 (en) 2006-11-21
MXPA03000856A (es) 2003-06-06
IN2002MU01649A (en:Method) 2004-12-11
PL365133A1 (en) 2004-12-27
ES2231521T3 (es) 2005-05-16
NO20030416L (no) 2003-02-05
CZ2003126A3 (cs) 2004-02-18
EA200300079A1 (ru) 2003-06-26
PT1305314E (pt) 2005-04-29
DOP2001000217A (es) 2002-10-30
BG107266A (bg) 2003-07-31
NZ523226A (en) 2003-07-25
HUP0302982A3 (en) 2005-01-28
AU7269001A (en) 2002-02-13
WO2002010171A1 (en) 2002-02-07
KR20030016430A (ko) 2003-02-26
MA26931A1 (fr) 2004-12-20
JP2004505087A (ja) 2004-02-19
AP2001002234A0 (en) 2001-09-30
TWI285643B (en) 2007-08-21
YU4703A (sh) 2006-01-16
CN1207297C (zh) 2005-06-22
DE60108398D1 (de) 2005-02-17
UA72631C2 (uk) 2005-03-15
ATE286901T1 (de) 2005-01-15
ZA200301457B (en) 2004-04-28

Similar Documents

Publication Publication Date Title
MX9702307A (es) Pirrolo (2,3-d)pirimidinas y su uso.
MY132106A (en) New pyridazin-3(2h)-one derivatives
HUP0104605A3 (en) Quinoline and quinoxaline compounds as pdgf-receptor and/or lck tyrosine kinase inhibitors, medicaments containing them and their use
EP1311269A4 (en) PROCESS FOR USE OF DIKETOPIPERAZINES AND COMPOSITIONS THEREOF CONTAINING THEM
UA103873C2 (ru) Гетероарильные производные мочевины как ингибиторы р38 и их применение
HUP0400908A3 (en) Pyrazole compounds useful as protein kinase inhibitors, their use and pharmaceutical compositions containing them
AU2002312933A1 (en) CDK inhibiting pyrimidines, production thereof and their use as medicaments
GEP20053479B (en) Pyrrolo[2,3-d]Pyrimidine Compounds, Pharmaceutical Composition Containing the Same and Use
HK1042091A1 (zh) 金剛烷衍生物
IL159120A0 (en) Cdk inhibiting pyrimidines, production thereof and their use as medicaments
GB0124933D0 (en) Chemical compounds
IL165392A (en) Use of vegfr modulator materials to prepare and protect liver growth drugs, products and kits that include them
MXPA03010761A (es) Combinaciones farmaceuticas.
AU2003298937A1 (en) Heterocyclic compounds, methods of making them and their use in therapy
CA2328280A1 (en) Thienopyrimidines
AU2002366736A1 (en) Masked phosphate containing nucleoside derivatives and their use as antivirals
GEP20053494B (en) Crystalline Therapeutic Agent
AU2003219900A1 (en) Antigene locks and therapeutic uses thereof
IL176524A0 (en) Ascorbic acid compounds, methods of synthesis and application use thereof
AU2002246983A1 (en) 1,2-disubstituted cyclic inhibitors of matrix metallorproteases and tnf-alpha
PL373247A1 (en) Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
WO2004043443A3 (en) Drugs for sexual dysfunctions
MXPA03003198A (es) 3,4-dihidro-pirido [1,2-a]pirimidinas sustituidas.
AU2003304115A8 (en) Dinoflagellate karlotoxins, methods of isolation and uses thereof
AU2002364804A1 (en) Use of l isomers of amino acid derivatives of hydroxyguanidine for producing no, pharmaceutical compositions containing same and pharmaceutical uses